The bacterial and plasmid vectors market size has grown rapidly in recent years. It will grow from $0.92 billion in 2025 to $1.02 billion in 2026 at a compound annual growth rate (CAGR) of 11.5%. The growth in the historic period can be attributed to growth in molecular biology research, widespread use of e. coli vectors, expansion of biotech research funding, protein expression needs, academic research growth.
The bacterial and plasmid vectors market size is expected to see rapid growth in the next few years. It will grow to $1.61 billion in 2030 at a compound annual growth rate (CAGR) of 11.9%. The growth in the forecast period can be attributed to gene therapy development, growth in biologics production, synthetic biology innovation, increased r&d investments, demand for high-efficiency vectors. Major trends in the forecast period include rising demand for recombinant protein production, growth in gene cloning applications, expansion of synthetic biology research, increasing use in academic research, advancements in vector engineering.
The increasing prevalence of cancer and infectious diseases is expected to drive the growth of the bacterial and plasmid vectors market in the coming years, as bacteria are used as vectors to deliver recombinant proteins into target cells for treatment. This rise in disease incidence is largely due to factors such as an aging population, lifestyle changes like poor diet and smoking, environmental pollution, and infectious agents. Bacterial and plasmid vectors play a crucial role in research by transporting therapeutic genes, vaccines, or genetic material that can stimulate immune responses or correct genetic defects, thereby preventing, treating, or managing these diseases by targeting underlying causes or enhancing the body’s defenses. For instance, in October 2024, the World Health Organization reported that approximately 10.8 million people worldwide contracted tuberculosis, with 55% men, 33% women, and 12% children and adolescents, and individuals living with HIV representing 6.1% of cases, highlighting how the growing prevalence of cancer and infectious diseases is fueling the bacterial and plasmid vectors market.
Major companies operating in the bacterial and plasmid vectors market are concentrating on developing advanced solutions, such as Innovative Plasmid, to improve the production of adeno-associated virus (AAV) vectors. An innovative plasmid is a plasmid (a small, circular DNA molecule) that has been specifically engineered or modified to perform advanced functions in biotechnology, gene therapy, or scientific research. For example, in March 2024, Polyplus, a France-based biotechnology company, introduced the pPLUS AAV-RC2 plasmid, designed to streamline the manufacturing process and provide a ready-to-use solution that enhances both efficiency and reliability in vector production. It includes unique features such as a ready-to-use format optimized for AAV2 production, substantial improvements in viral genome yield when used with Polyplus transfection reagents, and high-quality manufacturing at a GMP-compliant facility.
In August 2024, Merck KGaA, a pharmaceutical and life sciences company based in Germany, acquired Mirus Bio for an undisclosed amount. Through this acquisition, Merck intends to enhance its bacterial and plasmid vectors portfolio by incorporating Mirus Bio’s innovative non-viral gene delivery technologies and vector platforms, facilitating the development of advanced solutions for gene therapy and molecular biology research. Mirus Bio, a biotechnology company based in the US, specializes in non-viral vectors and gene delivery systems and has a strong track record in preclinical research and biopharmaceutical applications.
Major companies operating in the bacterial and plasmid vectors market are Sigma-Aldrich Inc., Thermo Fisher Scientific Inc., QIAGEN N.V., Promega Corporation, GenScript Biotech Corporation, Takara Bio Inc., New England Biolabs, Agilent Technologies, Bio-Rad Laboratories, ATUM, IBA GmbH, Clontech Laboratories Inc., DNA TwoPointO Inc., Creative Biogene, Creative Biomart, OriGene Technologies Inc., Addgene, Lucigen Corporation, Sino Biological Inc., Oxford Genetics Ltd.
North America was the largest region in the bacterial & plasmid vectors market in 2025. The Middle East is expected to be the fastest-growing region in the global bacterial & plasmid vectors market share during the forecast period. The regions covered in the bacterial and plasmid vectors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bacterial and plasmid vectors market report are China, India, Japan, Australia, Indonesia, South Korea, Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, Taiwan, New Zealand, UK, Germany, France, Italy, Spain, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Russia, Czech Republic, Poland, Romania, Ukraine, USA, Canada, Mexico, Brazil, Chile, Argentina, Colombia, Peru, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Tariffs have increased the cost of imported laboratory reagents, cloning kits, enzymes, and molecular biology tools used in research and biomanufacturing workflows. These impacts are most pronounced in North America and Europe, where laboratories rely heavily on global life science supply networks. Rising tariff related expenses have placed pressure on research budgets and procurement planning across academic and commercial institutions. This has affected purchasing cycles and the pace of experimental work. However, tariffs are also encouraging domestic biotech manufacturing, local supplier development, and stronger regional life science ecosystems over the long term.
The bacterial and plasmid vectors market research report is one of a series of new reports that provides bacterial and plasmid vectors market statistics, including bacterial and plasmid vectors industry global market size, regional shares, competitors with a bacterial and plasmid vectors market share, detailed bacterial and plasmid vectors market segments, market trends and opportunities, and any further data you may need to thrive in the bacterial and plasmid vectors industry. This bacterial and plasmid vectors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Bacterial and plasmid vectors are the tools used to introduce recombinant DNA into a host cell and play a crucial role in molecular cloning. This involves the process of generating DNA molecules and inserting them into a host cell. These vectors serve to transport recombinant DNA into bacteria, enabling them to produce proteins.
The primary hosts in bacterial and plasmid vectors include E. coli expression vectors as well as other bacterial expression vectors. The E. coli expression system allows for rapid recombinant protein production and supports large-scale, cost-efficient manufacturing. This approach is particularly suitable for non-glycosylated proteins, making it ideal for antigen expression and functional protein production. The various applications span genetics, molecular biology, bioinformatics, and more, and cover sectors such as hospitals, home care, specialty clinics, and others.
The bacterial and plasmid vectors market includes revenues earned by entities by cloning, transferring, and manipulating genes. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The bacterial and plasmid vectors market size is expected to see rapid growth in the next few years. It will grow to $1.61 billion in 2030 at a compound annual growth rate (CAGR) of 11.9%. The growth in the forecast period can be attributed to gene therapy development, growth in biologics production, synthetic biology innovation, increased r&d investments, demand for high-efficiency vectors. Major trends in the forecast period include rising demand for recombinant protein production, growth in gene cloning applications, expansion of synthetic biology research, increasing use in academic research, advancements in vector engineering.
The increasing prevalence of cancer and infectious diseases is expected to drive the growth of the bacterial and plasmid vectors market in the coming years, as bacteria are used as vectors to deliver recombinant proteins into target cells for treatment. This rise in disease incidence is largely due to factors such as an aging population, lifestyle changes like poor diet and smoking, environmental pollution, and infectious agents. Bacterial and plasmid vectors play a crucial role in research by transporting therapeutic genes, vaccines, or genetic material that can stimulate immune responses or correct genetic defects, thereby preventing, treating, or managing these diseases by targeting underlying causes or enhancing the body’s defenses. For instance, in October 2024, the World Health Organization reported that approximately 10.8 million people worldwide contracted tuberculosis, with 55% men, 33% women, and 12% children and adolescents, and individuals living with HIV representing 6.1% of cases, highlighting how the growing prevalence of cancer and infectious diseases is fueling the bacterial and plasmid vectors market.
Major companies operating in the bacterial and plasmid vectors market are concentrating on developing advanced solutions, such as Innovative Plasmid, to improve the production of adeno-associated virus (AAV) vectors. An innovative plasmid is a plasmid (a small, circular DNA molecule) that has been specifically engineered or modified to perform advanced functions in biotechnology, gene therapy, or scientific research. For example, in March 2024, Polyplus, a France-based biotechnology company, introduced the pPLUS AAV-RC2 plasmid, designed to streamline the manufacturing process and provide a ready-to-use solution that enhances both efficiency and reliability in vector production. It includes unique features such as a ready-to-use format optimized for AAV2 production, substantial improvements in viral genome yield when used with Polyplus transfection reagents, and high-quality manufacturing at a GMP-compliant facility.
In August 2024, Merck KGaA, a pharmaceutical and life sciences company based in Germany, acquired Mirus Bio for an undisclosed amount. Through this acquisition, Merck intends to enhance its bacterial and plasmid vectors portfolio by incorporating Mirus Bio’s innovative non-viral gene delivery technologies and vector platforms, facilitating the development of advanced solutions for gene therapy and molecular biology research. Mirus Bio, a biotechnology company based in the US, specializes in non-viral vectors and gene delivery systems and has a strong track record in preclinical research and biopharmaceutical applications.
Major companies operating in the bacterial and plasmid vectors market are Sigma-Aldrich Inc., Thermo Fisher Scientific Inc., QIAGEN N.V., Promega Corporation, GenScript Biotech Corporation, Takara Bio Inc., New England Biolabs, Agilent Technologies, Bio-Rad Laboratories, ATUM, IBA GmbH, Clontech Laboratories Inc., DNA TwoPointO Inc., Creative Biogene, Creative Biomart, OriGene Technologies Inc., Addgene, Lucigen Corporation, Sino Biological Inc., Oxford Genetics Ltd.
North America was the largest region in the bacterial & plasmid vectors market in 2025. The Middle East is expected to be the fastest-growing region in the global bacterial & plasmid vectors market share during the forecast period. The regions covered in the bacterial and plasmid vectors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bacterial and plasmid vectors market report are China, India, Japan, Australia, Indonesia, South Korea, Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, Taiwan, New Zealand, UK, Germany, France, Italy, Spain, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Russia, Czech Republic, Poland, Romania, Ukraine, USA, Canada, Mexico, Brazil, Chile, Argentina, Colombia, Peru, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Tariffs have increased the cost of imported laboratory reagents, cloning kits, enzymes, and molecular biology tools used in research and biomanufacturing workflows. These impacts are most pronounced in North America and Europe, where laboratories rely heavily on global life science supply networks. Rising tariff related expenses have placed pressure on research budgets and procurement planning across academic and commercial institutions. This has affected purchasing cycles and the pace of experimental work. However, tariffs are also encouraging domestic biotech manufacturing, local supplier development, and stronger regional life science ecosystems over the long term.
The bacterial and plasmid vectors market research report is one of a series of new reports that provides bacterial and plasmid vectors market statistics, including bacterial and plasmid vectors industry global market size, regional shares, competitors with a bacterial and plasmid vectors market share, detailed bacterial and plasmid vectors market segments, market trends and opportunities, and any further data you may need to thrive in the bacterial and plasmid vectors industry. This bacterial and plasmid vectors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Bacterial and plasmid vectors are the tools used to introduce recombinant DNA into a host cell and play a crucial role in molecular cloning. This involves the process of generating DNA molecules and inserting them into a host cell. These vectors serve to transport recombinant DNA into bacteria, enabling them to produce proteins.
The primary hosts in bacterial and plasmid vectors include E. coli expression vectors as well as other bacterial expression vectors. The E. coli expression system allows for rapid recombinant protein production and supports large-scale, cost-efficient manufacturing. This approach is particularly suitable for non-glycosylated proteins, making it ideal for antigen expression and functional protein production. The various applications span genetics, molecular biology, bioinformatics, and more, and cover sectors such as hospitals, home care, specialty clinics, and others.
The bacterial and plasmid vectors market includes revenues earned by entities by cloning, transferring, and manipulating genes. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Bacterial and Plasmid Vectors Market Characteristics
3. Bacterial and Plasmid Vectors Market Supply Chain Analysis
4. Global Bacterial and Plasmid Vectors Market Trends and Strategies
5. Bacterial and Plasmid Vectors Market Analysis of End Use Industries
7. Global Bacterial and Plasmid Vectors Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Bacterial and Plasmid Vectors Total Addressable Market (TAM) Analysis for the Market
9. Bacterial and Plasmid Vectors Market Segmentation
10. Bacterial and Plasmid Vectors Market Regional and Country Analysis
11. Asia-Pacific Bacterial and Plasmid Vectors Market
12. China Bacterial and Plasmid Vectors Market
13. India Bacterial and Plasmid Vectors Market
14. Japan Bacterial and Plasmid Vectors Market
15. Australia Bacterial and Plasmid Vectors Market
16. Indonesia Bacterial and Plasmid Vectors Market
17. South Korea Bacterial and Plasmid Vectors Market
18. Bangladesh Bacterial and Plasmid Vectors Market
19. Thailand Bacterial and Plasmid Vectors Market
20. Vietnam Bacterial and Plasmid Vectors Market
21. Malaysia Bacterial and Plasmid Vectors Market
22. Singapore Bacterial and Plasmid Vectors Market
23. Philippines Bacterial and Plasmid Vectors Market
24. Hong Kong Bacterial and Plasmid Vectors Market
25. New Zealand Bacterial and Plasmid Vectors Market
26. Taiwan Bacterial and Plasmid Vectors Market
27. South East Asia Bacterial and Plasmid Vectors Market
28. Western Europe Bacterial and Plasmid Vectors Market
29. UK Bacterial and Plasmid Vectors Market
30. Germany Bacterial and Plasmid Vectors Market
31. France Bacterial and Plasmid Vectors Market
32. Italy Bacterial and Plasmid Vectors Market
33. Spain Bacterial and Plasmid Vectors Market
34. Austria Bacterial and Plasmid Vectors Market
35. Belgium Bacterial and Plasmid Vectors Market
36. Denmark Bacterial and Plasmid Vectors Market
37. Finland Bacterial and Plasmid Vectors Market
38. Ireland Bacterial and Plasmid Vectors Market
39. Netherlands Bacterial and Plasmid Vectors Market
40. Norway Bacterial and Plasmid Vectors Market
41. Portugal Bacterial and Plasmid Vectors Market
42. Sweden Bacterial and Plasmid Vectors Market
42. Switzerland Bacterial and Plasmid Vectors Market
43. Eastern Europe Bacterial and Plasmid Vectors Market
44. Russia Bacterial and Plasmid Vectors Market
45. Czech Republic Bacterial and Plasmid Vectors Market
46. Poland Bacterial and Plasmid Vectors Market
47. Romania Bacterial and Plasmid Vectors Market
48. Ukraine Bacterial and Plasmid Vectors Market
49. North America Bacterial and Plasmid Vectors Market
50. USA Bacterial and Plasmid Vectors Market
51. Canada Bacterial and Plasmid Vectors Market
52. Mexico Bacterial and Plasmid Vectors Market
53. South America Bacterial and Plasmid Vectors Market
54. Brazil Bacterial and Plasmid Vectors Market
55. Chile Bacterial and Plasmid Vectors Market
56. Argentina Bacterial and Plasmid Vectors Market
57. Colombia Bacterial and Plasmid Vectors Market
58. Peru Bacterial and Plasmid Vectors Market
59. Middle East Bacterial and Plasmid Vectors Market
60. Saudi Arabia Bacterial and Plasmid Vectors Market
61. Israel Bacterial and Plasmid Vectors Market
62. Iran Bacterial and Plasmid Vectors Market
63. Turkey Bacterial and Plasmid Vectors Market
64. United Arab Emirates Bacterial and Plasmid Vectors Market
65. Africa Bacterial and Plasmid Vectors Market
66. Egypt Bacterial and Plasmid Vectors Market
67. Nigeria Bacterial and Plasmid Vectors Market
68. South Africa Bacterial and Plasmid Vectors Market
70. Bacterial and Plasmid Vectors Market Competitive Landscape and Company Profiles
71. Bacterial and Plasmid Vectors Market Other Major and Innovative Companies
74. Bacterial and Plasmid Vectors Market High Potential Countries, Segments and Strategies
75. Appendix
Executive Summary
Bacterial And Plasmid Vectors Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses bacterial and plasmid vectors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for bacterial and plasmid vectors? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The bacterial and plasmid vectors market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Host Type: E.Coli Expression Vectors; Other Bacterial Expression Vectors2) By Application: Genetics; Molecular Biology; Bioinformatics; Other Applications
3) By End Users: Academic And Research Institutes; Biotechnology And Biopharmaceutical Companies; Contract Research Organizations (CROs) And Contract Development And Manufacturing Organizations (CDMOs); Industrial And Synthetic Biology Companies; Government And Public Research Laboratories
Subsegments:
1) By E. Coli Expression Vectors: PET Vectors; PUC Vectors; PBR322 Vectors; Expression Systems For Protein Production2) By Other Bacterial Expression Vectors: Bacillus Subtilis Vectors; Pseudomonas Vectors; Lactococcus Lactis Vectors; Streptomyces Vectors
Companies Mentioned: Sigma-Aldrich Inc.; Thermo Fisher Scientific Inc.; QIAGEN N.V.; Promega Corporation; GenScript Biotech Corporation; Takara Bio Inc.; New England Biolabs; Agilent Technologies; Bio-Rad Laboratories; ATUM; IBA GmbH; Clontech Laboratories Inc.; DNA TwoPointO Inc.; Creative Biogene; Creative Biomart; OriGene Technologies Inc.; Addgene; Lucigen Corporation; Sino Biological Inc.; Oxford Genetics Ltd.
Countries: China; India; Japan; Australia; Indonesia; South Korea; Bangladesh; Thailand; Vietnam; Malaysia; Singapore; Philippines; Hong Kong; Taiwan; New Zealand; UK; Germany; France; Italy; Spain; Austria; Belgium; Denmark; Finland; Ireland; Netherlands; Norway; Portugal; Sweden; Switzerland; Russia; Czech Republic; Poland; Romania; Ukraine; USA; Canada; Mexico; Brazil; Chile; Argentina; Colombia; Peru; Saudi Arabia; Israel; Iran; Turkey; UAE; Egypt; Nigeria; South Africa.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Bacterial and Plasmid Vectors market report include:- Sigma-Aldrich Inc.
- Thermo Fisher Scientific Inc.
- QIAGEN N.V.
- Promega Corporation
- GenScript Biotech Corporation
- Takara Bio Inc.
- New England Biolabs
- Agilent Technologies
- Bio-Rad Laboratories
- ATUM
- IBA GmbH
- Clontech Laboratories Inc.
- DNA TwoPointO Inc.
- Creative Biogene
- Creative Biomart
- OriGene Technologies Inc.
- Addgene
- Lucigen Corporation
- Sino Biological Inc.
- Oxford Genetics Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 1.02 Billion |
| Forecasted Market Value ( USD | $ 1.61 Billion |
| Compound Annual Growth Rate | 11.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
